ACB $5.640 (-2.59%)

ACNNF $0.240 (-4.04%)

AERO $1.200 (-1.64%)

AGEEF $0.310 (-6.06%)

ALEAF $0.774 (-3.54%)

AMMJ $0.271 (-6.24%)

APHA $6.560 (0.77%)

ARNA $53.730 (-2.38%)

ATT:CNX $0.080 (0%)

ATTBF $0.031 (5.26%)

AUSA:CNX $0.890 (-3.26%)

AUSAF $0.683 (-1.3%)

AVXL $2.530 (-4.89%)

BAMM:CNX $0.840 (0%)

BBM:CNX $0.250 (-5.66%)

BBRRF $0.203 (-2.03%)

BE:CNX $0.065 (0%)

BIO:CNX $0.330 (-4.35%)

BLEVF $0.051 (-3.98%)

BLO:CNX $0.730 (0%)

BLOZF $0.536 (-3.44%)

BUDZ $0.429 (7.25%)

BXNG $0.498 (32.32%)

CADMF $0.673 (-10.91%)

CALI:CNX $0.120 (-4%)

CANN $1.020 (-2.86%)

CARA $22.930 (-4.42%)

CBII:CNX $0.150 (-6.25%)

CBIIF $0.121 (-6.9%)

CBWTF $0.662 (-1.06%)

CGC $24.890 (-0.96%)

CGRW $0.278 (4.91%)

CHOO:CNX $0.390 (-2.5%)

CHOOF $0.303 (0.83%)

CNAB $0.493 (8.24%)

CNBX $0.265 (1.94%)

CNGGF $1.290 (5.74%)

CODI $18.620 (-0.53%)

CPMD $2.060 (0%)

CRBP $5.300 (-5.36%)

CRON $11.400 (-1.55%)

CROP:CNX $0.105 (-4.55%)

CRTPF $3.480 (-6.73%)

CRXPF $0.078 (-7.59%)

CSI:CNX $0.890 (-11%)

CTST $1.850 (-4.15%)

CURR $4.200 (-4.55%)

CVSI $3.660 (-4.01%)

DIGP $0.120 (0.08%)

DXBRF $0.702 (-2.77%)

EAPH $0.004 (-2.63%)

EAT:CNX $0.155 (0%)

EEVVF $0.242 (-6.3%)

EMHTF $1.470 (-2.5%)

EPWCF $0.075 (-1.07%)

EVIO $0.685 (0.74%)

FFRMF $0.050 (-17.5%)

FFT:CNX $0.065 (-13.33%)

FNNZF $0.093 (-7.4%)

FSDDF $0.086 (1.54%)

GGTTF $0.228 (-8.8%)

GLDFF $0.039 (-1.53%)

GLH:CNX $0.050 (0%)

GLNNF $0.048 (-3.6%)

GNBT $2.121 (-1.81%)

GRIN:CNX $0.160 (0%)

GRWG $5.030 (4.14%)

GSTR:CNX $0.115 (-17.86%)

GTBIF $7.990 (-3.27%)

GTII:CNX $10.550 (-4.09%)

GWPH $145.460 (-1.28%)

HEXO $4.010 (0.75%)

HHPHF $0.160 (0%)

HLSPY $0.623 (0%)

HMLSF $10.957 (-2.67%)

HMPPF $0.498 (0%)

HRVOF $0.416 (-2.35%)

HSTRF $0.244 (0%)

HUGE:CNX $0.110 (0%)

IAN:CNX $3.350 (1.21%)

IGC $1.070 (-3.6%)

IGXT $0.420 (0%)

IIPR $101.500 (-4.55%)

IMLFF $0.180 (-4.76%)

INQD $0.014 (-17.99%)

IONC:CNX $0.150 (7.14%)

IONKF $0.120 (16.5%)

ISOL:CNX $0.375 (-2.6%)

ISOLF $0.283 (-5.03%)

ITHUF $2.480 (-0.4%)

IVITF $0.261 (-5.09%)

JWCAF $0.471 (3.09%)

KALTF $0.038 (1.65%)

KBEV:CNX $0.230 (6.98%)

KBEVF $0.175 (2.34%)

KHRNF $1.200 (-9.5%)

KSHB $3.860 (-3.22%)

LDS:CNX $0.150 (-6.25%)

LDSYF $0.118 (-3.2%)

LHS:CNX $0.400 (-2.44%)

LHSIF $0.300 (-3.32%)

LOVE:CNX $0.150 (3.45%)

LXLLF $0.569 (-10.62%)

LXRP $0.701 (-4.01%)

LXX:CNX $0.920 (-10.68%)

MCIG $0.060 (-1.31%)

MDCL $3.020 (0.33%)

MEDIF $3.830 (-0.39%)

MGWFF $0.063 (15.05%)

MICWF $0.152 (0.26%)

MJ:CNX $0.290 (9.43%)

MJNA $0.044 (-2.78%)

MNTR $0.225 (-2.17%)

MRRCF $0.195 (8.28%)

MWM:CNX $0.200 (2.56%)

MYM:CNX $0.270 (1.89%)

MYMMF $0.202 (-2.4%)

NCNNF $0.600 (-4.75%)

NDVAF $0.295 (-4.9%)

NGW:CNX $0.255 (4.08%)

NRXCF $0.046 (8.36%)

NSPDF $0.088 (3.76%)

NTEC $0.460 (2.91%)

NVTQF $0.157 (0%)

NWKRF $0.424 (0%)

NXGWF $0.194 (-2.76%)

NXTTF $0.300 (0%)

OH:CNX $6.950 (-5.95%)

ORHOF $5.249 (-5.68%)

OWCP $0.008 (0%)

PHGI:CNX $0.280 (3.7%)

PHGRF $0.213 (5.67%)

PHVAF $0.240 (-3.61%)

PILL:CNX $0.600 (0%)

PKG:CNX $0.175 (-7.89%)

PLPRF $3.323 (-4.04%)

PLUS:CNX $4.470 (-2.83%)

PMCB $0.037 (0.52%)

PNPL $0.260 (0%)

POTN $0.050 (-3.94%)

PRCNF $0.060 (-9.76%)

PTNYF $0.137 (-3.92%)

QCA:CNX $0.150 (-6.25%)

RDDTF $0.530 (0.95%)

RLLVF $0.047 (-4.52%)

RMHB $0.068 (6.25%)

RQB:CNX $0.410 (-1.2%)

RQHTF $0.247 (9.14%)

RVVQF $0.308 (-0.55%)

SLNG:CNX $0.920 (1.1%)

SMG $102.980 (-5.44%)

SNN:CNX $1.040 (-0.95%)

SNNVF $0.780 (-0.89%)

SOL:CNX $1.270 (-5.93%)

SOLCF $0.950 (-5.95%)

SPLIF $0.116 (1.2%)

SPRWF $1.100 (-2.65%)

SRNA $0.119 (45.16%)

STEM:CNX $1.290 (0%)

STMH $1.000 (3.09%)

SUN:CNX $0.330 (-5.71%)

TBPMF $0.250 (-1.14%)

TCAN:CNX $0.720 (-10%)

TCNAF $0.628 (0%)

TER:CNX $6.350 (-7.3%)

TGEN $2.680 (1.52%)

TGIF:CNX $0.350 (-2.78%)

TGIFF $0.267 (-2.22%)

THC:CNX $0.160 (-3.03%)

THCBF $0.116 (-3.32%)

TLRY $28.290 (-2.48%)

TOKI:CNX $0.050 (0%)

TRLFF $0.216 (11.37%)

TRPX $2.270 (-3.81%)

TRSSF $4.780 (-7%)

TRTC $0.394 (0.63%)

TURV $0.285 (-4.97%)

VAPN:CNX $1.790 (1.7%)

VBIO $0.225 (12.5%)

VIDA:CNX $0.330 (0%)

VIN:CNX $0.180 (0%)

VPRB $0.090 (28.57%)

VRNDF $0.660 (1.79%)

VRT:CNX $0.360 (-10%)

VRTHF $0.275 (0%)

VVCIF $0.332 (-0.78%)

WAYL:CNX $0.740 (0%)

WDDMF $1.170 (2.12%)

WLDFF $0.253 (-6.12%)

XXII $1.990 (0.51%)

ZDPY $0.407 (0%)

ZYNE $10.960 (-3.27%)

Technical420 Site Search

Returned 91 result(s).

Cardiol Therapeutics’ Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer of its pure pharmaceutical CBD, was selected to…

Premier Health Group Has Been Red Hot On The Acquisition Trail

2019 has been a banner year for Premier Health Group Inc. (PHGI.CN) (PHGRF) and this is an opportunity that we have been closely watching. Earlier this year, the company completed the acquisition of Cloud Practice and we believe that this was a transformational acquisition for Premier Health. This acquisition has…

Cardiol Is Leveraging Cutting Edge Technologies To Bring Game-Changing Products To Market

In late 2018, Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) commenced trading on the Toronto Stock Exchange (TSX) and we have been closely following the Canadian biotech company. We believe that the biotech industry will be one of the greatest beneficiaries of the legal cannabis movement and for this reason, investor…

Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon

Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave") and Intrexon Corporation (NASDAQ: XON) ("Intrexon") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars…

Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001

Tetra Bio-Pharma Inc. today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as…

IntelGenx Signs Letter of Intent with Tilray® to Enter Into a World-Wide Agreement To Produce Cannabis-Infused VersaFilm™ Products

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) today announced that it has executed a non-binding letter of intent (the “LOI”) with Tilray, Inc. (https://www.globenewswire.com/Tracker...) (NASDAQ:TLRY) (“Tilray(®)”), a global leader in cannabis research, cultivation, production and distribution, to co-develop and commercialize oral film products infused with recreational and medical cannabis (“cannabis-infused VersaFilm™”), in…

InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced that is has received final approval for the listing of the Company's common shares (the "Common Shares") on the Toronto Stock Exchange (the "TSX"). The Common Shares…

InMed Receives Conditional Approval to List on the Toronto Stock Exchange

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to list its common shares ("Common Shares") on the TSX.  Final approval…

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS).…

Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC…

Older Posts »

Search Again